312 related articles for article (PubMed ID: 15526230)
1. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D
Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230
[TBL] [Abstract][Full Text] [Related]
2. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
[TBL] [Abstract][Full Text] [Related]
5. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy.
Kriegmair M; Zaak D; Rothenberger KH; Rassweiler J; Jocham D; Eisenberger F; Tauber R; Stenzl A; Hofstetter A
J Urol; 2002 Aug; 168(2):475-8. PubMed ID: 12131291
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].
Danil'chenko DI; Koenig F; Riedl K; Schnorr D; Waldman A; Al-Shukri S; Loening SA
Vopr Onkol; 2003; 49(6):734-7. PubMed ID: 14976918
[TBL] [Abstract][Full Text] [Related]
7. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
[TBL] [Abstract][Full Text] [Related]
8. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
9. [Fluorescence cystoscopy in the diagnostics and treatment of superficial urinary bladder tumors].
Babjuk M; Soukup V; Petrík R; Pavlík I; Jirsa M; Dvorácek J; Pecen L
Cas Lek Cesk; 2005; 144 Suppl 2():15-8. PubMed ID: 16277179
[TBL] [Abstract][Full Text] [Related]
10. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
[TBL] [Abstract][Full Text] [Related]
11. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
Schmidbauer J; Witjes F; Schmeller N; Donat R; Susani M; Marberger M;
J Urol; 2004 Jan; 171(1):135-8. PubMed ID: 14665861
[TBL] [Abstract][Full Text] [Related]
12. [ALA fluorescent diagnosis of bladder cancer].
Al'-Shukri SKh; Danil'chenko DI; Kënig F; Shnorr D
Urologiia; 2000; (5):48-50. PubMed ID: 11392226
[TBL] [Abstract][Full Text] [Related]
13. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
[TBL] [Abstract][Full Text] [Related]
14. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
15. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
Witjes JA; Douglass J
Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
[TBL] [Abstract][Full Text] [Related]
16. [Hexvix induced fluorescence blue light cystoscopy--a new perspective in superficial bladder tumors diagnosis].
Geavlete B; Mulţescu R; Georgescu D; Geavlete P
Chirurgia (Bucur); 2008; 103(5):559-64. PubMed ID: 19260632
[TBL] [Abstract][Full Text] [Related]
17. Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
Ahmad S; Aboumarzouk O; Somani B; Nabi G; Kata SG
BJU Int; 2012 Dec; 110(11 Pt B):E596-600. PubMed ID: 22758907
[TBL] [Abstract][Full Text] [Related]
18. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
Schumacher MC; Holmäng S; Davidsson T; Friedrich B; Pedersen J; Wiklund NP
Eur Urol; 2010 Feb; 57(2):293-9. PubMed ID: 19913351
[TBL] [Abstract][Full Text] [Related]
19. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.
Hungerhuber E; Stepp H; Kriegmair M; Stief C; Hofstetter A; Hartmann A; Knuechel R; Karl A; Tritschler S; Zaak D
Urology; 2007 Feb; 69(2):260-4. PubMed ID: 17320660
[TBL] [Abstract][Full Text] [Related]
20. [Role of fluorescent control in raising radicality of surgical treatment for superficial bladder cancer].
Matveev BP; Kudashev BV; Bukharkin BV; Romanov VA; Rubanov IuV
Urologiia; 2000; (3):22-4. PubMed ID: 11186703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
